GSE92415

Characterization of molecular response to Golimumab in Ulcerative Colitis by mucosal biopsy mRNA expression profiling: results from PURSUIT-SC induction study

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

162 case / 21 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Source
GEO
Assay
microarray
Organism
Homo sapiens
Whole-study samples
183 samples
Specimen
Biopsy
Reported/interpreted study design
Treatment vs control Design classification does not establish patient pairs.
Comparison type
Tumor vs normal
Contributors
Li K, Telesco S, Rutgeerts P, Sandborn W, Marano C, Ma K, Johanns J, Zhang H, Strauss R, Reinisch W, Colombel J, Brodmerkel C
Contact name
K Li
Submission date
2016-12-14
Last update
2022-06-06
Organization
Janssen R&D
Department
Not available
Public date
2018-12-03
Experiment types
Expression profiling by array
Platforms
GPL13158 [HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate
Series type
Series
SubSeries
Not available
BioProject
PRJNA357497

Summary

To evaluate the effects of induction treatment with an anti-TNF, golimumab (GLM), on gene expression in patients with moderately to severely active ulcerative colitis (UC), we performed mRNA microarray studies on colon biopsies from patients who participated in the PURSUIT-SC induction study and additional samples from 21 healthy subjects. Comparisons were conducted between baseline UC (n=87) and healthy (n=21), and week 6 (n=75) vs. baseline (n=87) prior to treatment. A significant difference was observed in mRNA expression between UC and healthy. Significant expression modulations were identified in patients who responded to GLM at week 6, but not GLM-treated non-responders or placebo-treated subjects.

Overall design

Mucosal biopsy samples (162 UC from the PURSUIT-SC induction study and 21 healthy) were collected for RNA extraction and microarray analysis.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
183 GSM samples
 Primary source
recount3

Planned trusted source for processed count availability.

 No match found
Expression Atlas

Planned source for curated expression experiment links.

 No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

21 linked publications 21 DOIs

Primary publication

  1. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 2014

Related publications

  1. Identification of hypoxia-associated genes as potential diagnostic biomarkers for ulcerative colitis. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2026
  2. Knockdown of LOXL2 suppresses cuproptosis induced by H(2)O(2) to inhibited the procession of ulcerative colitis. International immunopharmacology, 2025
  3. Identification of cholesterol homeostasis related genes and potential pathogenesis mechanisms in ulcerative colitis. The Journal of steroid biochemistry and molecular biology, 2025
  4. Identification of subclusters and prognostic genes based on GLS-associated molecular signature in ulcerative colitis. Scientific reports, 2024
  5. Integrative biomarker discovery and immune profiling for ulcerative colitis: a multi-methodological approach. Scientific reports, 2024
  6. Formylated Peptide Receptor-1-Mediated Gut Inflammation as a Therapeutic Target in Inflammatory Bowel Disease. Crohn's & colitis 360, 2024
  7. Identification of O-glycosylation related genes and subtypes in ulcerative colitis based on machine learning. PloS one, 2024
  8. Screening and validation of 3'-Methoxydaidzein as a therapeutic agent in ulcerative colitis based on disulfidptosis-associated molecular clusters. PloS one, 2025
  9. Analysis of common differential gene expression between rheumatoid arthritis and ulcerative colitis. PloS one, 2026
  10. Single-Cell RNA-Sequencing Analysis of Colonic Lamina Propria Immune Cells Reveals the Key Immune Cell-Related Genes of Ulcerative Colitis. Journal of inflammation research, 2023
  11. Discovery and Validation of Ferroptosis-Associated Genes of Ulcerative Colitis. Journal of inflammation research, 2024
  12. Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis. Frontiers in genetics, 2021
  13. Multi-omics derivation of a core gene signature for predicting therapeutic response and characterizing immune dysregulation in inflammatory bowel disease. Frontiers in immunology, 2025
  14. Molecular mechanisms of ferroptosis in ulcerative colitis: insights from machine learning, WGCNA, and immune cell infiltration analysis. Frontiers in immunology, 2025
  15. Comprehensive analysis of anoikis-related gene signature in ulcerative colitis using machine learning algorithms. Frontiers in medicine, 2025
  16. An integrated machine learning framework for developing and validating diagnostic models and drug predictions based on ulcerative colitis genes. Frontiers in medicine, 2025
  17. Interplay of Transcriptomic Regulation, Microbiota, and Signaling Pathways in Lung and Gut Inflammation-Induced Tumorigenesis. Cells, 2024
  18. Bile Derivative T3K Ameliorates Colitis by Regulating the Intestinal Microbiota-Bile Acid Axis. Pharmaceutics, 2025
  19. Gegen Qinlian Decoction Attenuates Ulcerative Colitis by Inhibiting PANoptosis: A Multi-Omics and Experimental Study. Journal of visualized experiments : JoVE, 2026
  20. Identifying biomarkers associated with the diagnosis of ulcerative colitis via bioinformatics and machine learning. Mathematical biosciences and engineering : MBE, 2023
Available

Metadata Quality Components

Persisted metadata quality

100 pts
Clarity
100%
Weight
100 pts

Sample source clarity: All samples have source metadata and clear GSE/GSM accessions. Group clarity: Rule-based grouping found both case and control samples. Disease clarity: Disease or condition metadata normalized. Tissue clarity: Anatomical source metadata normalized. Treatment clarity: No unclear treatment split detected in the sample metadata. Replicate clarity: No pooled sample or technical replicate flags detected. Data availability clarity: Dataset-level processed or raw data availability is explicit.

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Treated 162 samples
  • Likely control group Healthy control 21 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a treatment/control experiment. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Interpreted disease metadata: Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 21 publications; 21 DOIs available: PMID 23735746, PMID 34306038, PMID 37322958, PMID 38026254, PMID 38352118.
  • Publication context: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.. Gastroenterology, 2014. PMID 23735746. DOI 10.1053/j.gastro.2013.05.048.
  • Publication context: Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis.. Frontiers in genetics, 2021. PMID 34306038. DOI 10.3389/fgene.2021.697514.
  • Publication context: Identifying biomarkers associated with the diagnosis of ulcerative colitis via bioinformatics and machine learning.. Mathematical biosciences and engineering : MBE, 2023. PMID 37322958. DOI 10.3934/mbe.2023476.
  • Publication context: 18 additional linked PubMed publications are available.

Cautions

  • Downgraded for tissue search because it is a treatment/control experiment.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

showing 500 of 1134 fields

Sample Group Preview

showing 71 of 183 preview rows Show Hide
Study totals: Case 162 | Control 21 | Unassigned 0 | Excluded 0 | Ambiguous 0 showing 71 of 183 preview rows
Group Role Accession Title Source / characteristics Reason
Treated Case GSM2429346 T17p1_A8 Tissue biopsy Tissue: Colon mucosa; Subject: 6402-00008; Disease: Ulcerative Colitis (UC); Age: 77; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429347 T17p2_F4 Tissue biopsy Tissue: Colon mucosa; Subject: 7783-00005; Disease: Ulcerative Colitis (UC); Age: 34; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429348 T17p1_A11 Tissue biopsy Tissue: Colon mucosa; Subject: 6502-00028; Disease: Ulcerative Colitis (UC); Age: 27; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429349 T17p2_B8 Tissue biopsy Tissue: Colon mucosa; Subject: 7796-00003; Disease: Ulcerative Colitis (UC); Age: 63; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429350 T17p2_B7 Tissue biopsy Tissue: Colon mucosa; Subject: 7602-00001; Disease: Ulcerative Colitis (UC); Age: 39; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429351 T17p2_C1 Tissue biopsy Tissue: Colon mucosa; Subject: 7414-00018; Disease: Ulcerative Colitis (UC); Age: 28; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 11 Explicit characteristic comparison arm detected.
Treated Case GSM2429352 T17p1_D4 Tissue biopsy Tissue: Colon mucosa; Subject: 6705-00016; Disease: Ulcerative Colitis (UC); Age: 50; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 11 Explicit characteristic comparison arm detected.
Treated Case GSM2429353 T17p1_C8 Tissue biopsy Tissue: Colon mucosa; Subject: 6404-00026; Disease: Ulcerative Colitis (UC); Age: 51; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429354 T17p2_A4 Tissue biopsy Tissue: Colon mucosa; Subject: 7756-00011; Disease: Ulcerative Colitis (UC); Age: 46; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429355 T17p2_A7 Tissue biopsy Tissue: Colon mucosa; Subject: 7785-00003; Disease: Ulcerative Colitis (UC); Age: 30; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 11 Explicit characteristic comparison arm detected.
Treated Case GSM2429356 T17p1_E10 Tissue biopsy Tissue: Colon mucosa; Subject: 7204-00011; Disease: Ulcerative Colitis (UC); Age: 38; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429357 T17p1_H4 Tissue biopsy Tissue: Colon mucosa; Subject: 6402-00007; Disease: Ulcerative Colitis (UC); Age: 49; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429358 T17p2_B5 Tissue biopsy Tissue: Colon mucosa; Subject: 7530-00008; Disease: Ulcerative Colitis (UC); Age: 56; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 6 Explicit characteristic comparison arm detected.
Treated Case GSM2429359 T17p2_H4 Tissue biopsy Tissue: Colon mucosa; Subject: 7530-00011; Disease: Ulcerative Colitis (UC); Age: 63; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429360 T17p1_G1 Tissue biopsy Tissue: Colon mucosa; Subject: 7207-00021; Disease: Ulcerative Colitis (UC); Age: 27; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429361 T17p1_A10 Tissue biopsy Tissue: Colon mucosa; Subject: 6404-00030; Disease: Ulcerative Colitis (UC); Age: 30; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429362 T17p1_B2 Tissue biopsy Tissue: Colon mucosa; Subject: 6404-00017; Disease: Ulcerative Colitis (UC); Age: 63; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429363 T17p1_F2 Tissue biopsy Tissue: Colon mucosa; Subject: 7213-00008; Disease: Ulcerative Colitis (UC); Age: 25; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429364 T17p2_C3 Tissue biopsy Tissue: Colon mucosa; Subject: 7781-00003; Disease: Ulcerative Colitis (UC); Age: 36; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 11 Explicit characteristic comparison arm detected.
Treated Case GSM2429365 T17p1_A4 Tissue biopsy Tissue: Colon mucosa; Subject: 6177-00015; Disease: Ulcerative Colitis (UC); Age: 23; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429366 T17p2_G3 Tissue biopsy Tissue: Colon mucosa; Subject: 7753-00004; Disease: Ulcerative Colitis (UC); Age: 51; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429367 T17p2_G1 Tissue biopsy Tissue: Colon mucosa; Subject: 7414-00019; Disease: Ulcerative Colitis (UC); Age: 24; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429368 T17p1_E6 Tissue biopsy Tissue: Colon mucosa; Subject: 7213-00010; Disease: Ulcerative Colitis (UC); Age: 52; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429369 T17p2_E1 Tissue biopsy Tissue: Colon mucosa; Subject: 7530-00002; Disease: Ulcerative Colitis (UC); Age: 57; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429370 T17p1_D5 Tissue biopsy Tissue: Colon mucosa; Subject: 6705-00018; Disease: Ulcerative Colitis (UC); Age: 20; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429371 T17p2_A6 Tissue biopsy Tissue: Colon mucosa; Subject: 7414-00020; Disease: Ulcerative Colitis (UC); Age: 27; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 12 Explicit characteristic comparison arm detected.
Treated Case GSM2429372 T17p1_B1 Tissue biopsy Tissue: Colon mucosa; Subject: 6502-00022; Disease: Ulcerative Colitis (UC); Age: 30; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429373 T17p2_A1 Tissue biopsy Tissue: Colon mucosa; Subject: 7785-00001; Disease: Ulcerative Colitis (UC); Age: 29; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 11 Explicit characteristic comparison arm detected.
Treated Case GSM2429374 T17p2_B1 Tissue biopsy Tissue: Colon mucosa; Subject: 7787-00002; Disease: Ulcerative Colitis (UC); Age: 46; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429375 T17p1_C10 Tissue biopsy Tissue: Colon mucosa; Subject: 6404-00031; Disease: Ulcerative Colitis (UC); Age: 46; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429376 T17p1_C3 Tissue biopsy Tissue: Colon mucosa; Subject: 7179-00002; Disease: Ulcerative Colitis (UC); Age: 46; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429377 T17p2_B6 Tissue biopsy Tissue: Colon mucosa; Subject: 7416-00009; Disease: Ulcerative Colitis (UC); Age: 34; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429378 T17p1_C7 Tissue biopsy Tissue: Colon mucosa; Subject: 7026-00028; Disease: Ulcerative Colitis (UC); Age: 50; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429379 T17p2_G5 Tissue biopsy Tissue: Colon mucosa; Subject: 7528-00001; Disease: Ulcerative Colitis (UC); Age: 63; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429380 T17p2_F6 Tissue biopsy Tissue: Colon mucosa; Subject: 7601-00002; Disease: Ulcerative Colitis (UC); Age: 27; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429381 T17p1_G3 Tissue biopsy Tissue: Colon mucosa; Subject: 7354-00009; Disease: Ulcerative Colitis (UC); Age: 44; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 9 Explicit characteristic comparison arm detected.
Treated Case GSM2429382 T17p2_F7 Tissue biopsy Tissue: Colon mucosa; Subject: 7460-00002; Disease: Ulcerative Colitis (UC); Age: 54; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429383 T17p1_A12 Tissue biopsy Tissue: Colon mucosa; Subject: 7783-00003; Disease: Ulcerative Colitis (UC); Age: 71; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429384 T17p1_G9 Tissue biopsy Tissue: Colon mucosa; Subject: 7204-00013; Disease: Ulcerative Colitis (UC); Age: 39; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 12 Explicit characteristic comparison arm detected.
Treated Case GSM2429385 T17p1_B5 Tissue biopsy Tissue: Colon mucosa; Subject: 6705-00017; Disease: Ulcerative Colitis (UC); Age: 36; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429386 T17p1_E7 Tissue biopsy Tissue: Colon mucosa; Subject: 6179-00009; Disease: Ulcerative Colitis (UC); Age: 32; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429387 T17p2_D3 Tissue biopsy Tissue: Colon mucosa; Subject: 7785-00002; Disease: Ulcerative Colitis (UC); Age: 64; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 10 Explicit characteristic comparison arm detected.
Treated Case GSM2429388 T17p2_H7 Tissue biopsy Tissue: Colon mucosa; Subject: 7790-00002; Disease: Ulcerative Colitis (UC); Age: 27; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429389 T17p1_E12 Tissue biopsy Tissue: Colon mucosa; Subject: 7746-00010; Disease: Ulcerative Colitis (UC); Age: 69; Treatment: Golimumab; Visit: Week 0; Wk6response: No; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429390 T17p2_C6 Tissue biopsy Tissue: Colon mucosa; Subject: 7601-00001; Disease: Ulcerative Colitis (UC); Age: 59; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 8 Explicit characteristic comparison arm detected.
Treated Case GSM2429391 T17p2_A2 Tissue biopsy Tissue: Colon mucosa; Subject: 7530-00004; Disease: Ulcerative Colitis (UC); Age: 42; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 6 Explicit characteristic comparison arm detected.
Treated Case GSM2429392 T17p1_E3 Tissue biopsy Tissue: Colon mucosa; Subject: 6501-00019; Disease: Ulcerative Colitis (UC); Age: 20; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429393 T17p1_H1 Tissue biopsy Tissue: Colon mucosa; Subject: 6716-00010; Disease: Ulcerative Colitis (UC); Age: 69; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 6 Explicit characteristic comparison arm detected.
Treated Case GSM2429394 T17p2_H8 Tissue biopsy Tissue: Colon mucosa; Subject: 7460-00004; Disease: Ulcerative Colitis (UC); Age: 45; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 7 Explicit characteristic comparison arm detected.
Treated Case GSM2429395 T17p2_D7 Tissue biopsy Tissue: Colon mucosa; Subject: 7602-00004; Disease: Ulcerative Colitis (UC); Age: 36; Treatment: Golimumab; Visit: Week 0; Wk6response: Yes; Mayo score: 9 Explicit characteristic comparison arm detected.
112 additional case samples are hidden from this preview.
Healthy control Control GSM2429455 Colon-NHC-UC_E1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429456 Colon-NHC-UC_G4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429457 Colon-NHC-UC_A2 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429458 Colon-NHC-UC_A4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429459 Colon-NHC-UC_D1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429460 Colon-NHC-UC_H1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429461 Colon-NHC-UC_B2 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429462 Colon-NHC-UC_G1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429463 Colon-NHC-UC_F2 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429464 Colon-NHC-UC_D2 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429465 Colon-NHC-UC_D4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429466 Colon-NHC-UC_B1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429467 Colon-NHC-UC_H4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429468 Colon-NHC-UC_C1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429469 Colon-NHC-UC_F1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429470 Colon-NHC-UC_B4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429471 Colon-NHC-UC_C4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429472 Colon-NHC-UC_A1 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429473 Colon-NHC-UC_F4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429474 Colon-NHC-UC_C2 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.
Healthy control Control GSM2429475 Colon-NHC-UC_E4 Tissue biopsy Tissue: Colon mucosa; Disease: Healthy; Treatment: Healthy; Visit: Healthy; Wk6response: Healthy; Mayo score: . Explicit characteristic control arm detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.